Literature DB >> 10996920

[HIV-1 associated encephalopathy and myelopathy].

C Eggers1.   

Abstract

HIV-1-associated encephalopathy (HIVE) remains an important manifestation of advanced HIV infection despite recent progress in antiretroviral therapy. This is in part due to particular pharmacological and virological characteristics of the central nervous system (CNS). HIVE is characterized by a "subcortical" dementia with psychomotor slowing as well as memory and concentration deficits. An invariable finding are deficits of central motor function. Pathogenetically, an enhanced viral replication in immunocompetent CNS cells is believed to be a requirement. This leads to neurotoxic effects directly elicited by viral products as well as indirectly by the immune response to virus infection. HIV-1 myelopathy (HIVM) is the other CNS manifestation of late HIV infection. The present consensus paper recommends diagnostic and therapeutic procedures in HIVE and HIVM and outlines the current research.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10996920     DOI: 10.1007/s001150050646

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  3 in total

Review 1.  [Differential diagnostics of dementia type diseases].

Authors:  W Reith; R Mühl-Benninghaus
Journal:  Radiologe       Date:  2015-05       Impact factor: 0.635

2.  [Cerebrospinal fluid parameters in various stages of HIV infection. Results of cross-sectional and longitudinal analysis].

Authors:  B Kammer-Suhr; Ch Heese; A Kulschewski; D Reichelt; St Evers; I-W Husstedt
Journal:  Nervenarzt       Date:  2003-08       Impact factor: 1.214

3.  Fewer neurocognitive deficits and less brain atrophy by third ventricle measurement in PLWH treated with modern ART: A prospective analysis.

Authors:  Dominic Kaddu-Mulindwa; Matthias Heit; Gudrun Wagenpfeil; Moritz Bewarder; Klaus Fassbender; Stefanie Behnke; Umut Yilmaz; Mathias Fousse
Journal:  Front Neurol       Date:  2022-08-23       Impact factor: 4.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.